Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance

Frontiers in Pharmacology

Volumn 3 MAY, Issue , 2012, Pages

  Dickschen, Kristin ^a,b   Willmann, Stefan ^b   Thelen, Kirstin ^b   Lippert, Jörg ^b   Hempel, Georg ^a   Eissing, Thomas ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b BAYER AG   (Germany)

Author keywords

Cyp2d6; Endoxifen; Pbpk; Pharmacokinetics; Population simulation; Tamoxifen

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2D6; ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; CYP2D6 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER CLEARANCE; MALE; MOLECULAR WEIGHT; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PLASMA CONCENTRATION-TIME CURVE; RAT; SIMULATION; SINGLE DRUG DOSE; STEADY STATE;

EID: 84866016004     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00092     Document Type: Article

References (84)

1. Ahmad, A., Shahabuddin, S., Sheikh, S., Kale, P., Krishnappa, M., Rane, R. C., and Ahmad, I. (2010). Endoxifen,a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin. Pharmacol. Ther. 88, 814-817.
2. Bergstrom, C. A., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., and Artursson, P. (2003). Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46, 558-570.
3. Bijl, M., Van Schaik, R., Lammers, L., Hofman,A.,Vulto,A.,Van Gelder, T., Stricker,B.,and Visser,L. (2009). The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 118, 125-130.
4. Blevins-Primeau, A. S., Sun, D., Chen, G., Sharma, A. K., Gallagher, C. J., Amin, S., and Lazarus, P. (2009). Functional significance of UDPglucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 69, 1892-1900.
5. Borges, S., Desta, Z., Li, L., Skaar, T. C., Ward, B. A., Nguyen, A., Jin, Y., Storniolo, A. M., Nikoloff, D. M., Wu, L., Hillman, G., Hayes, D. F., Stearns, V., and Flockhart, D. A. (2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74.
6. Bourassa, P., Dubeau, S., Maharvi, G. M., Fauq, A. H., Thomas, T. J., and Tajmir-Riahi, H. A. (2011). Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin. Biochimie 93, 1089-1101.
7. Bratherton, D. G., Brown, C. H., Buchanan, R., Hall, V., Kingsley Pillers, E. M., Wheeler, T. K., and Williams, C. J. (1984). A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br. J. Cancer 50, 199-205.
8. Brauch, H. B., Schroth, W., Ingle, J. N., and Goetz, M. P. (2011). CYP2D6 and tamoxifen: awaiting the denouement. J. Clin. Oncol. 29, 4589-4590.
9. Buchanan, C. M., Buchanan, N. L., Edgar, K. J., Little, J. L., Malcolm, M. O., Ruble, K. M., Wacher, V. J., and Wempe, M. F. (2007). Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenylbeta-cyclodextrin formulations. J. Pharm. Sci. 96, 644-660.
10. Buckley, M. M., and Goa, K. L. (1989). Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs37, 451-490.
11. Buzdar, A. U., Hortobagyi, G. N., Frye, D., Ho, D., Booser, D. J., Valero, V., Holmes, F. A., Birmingham, B. K., Bui, K., and Yeh, C. (1994). Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twicedaily tamoxifen regimens for breast cancer. J. Clin. Oncol. 12, 50-54.
12. Choi, J. S., and Kang, K. W. (2008). Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch. Pharm. Res. 31, 1631-1636.
13. Coller, J. K., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., Nussler, A., Neuhaus, P., Zanger, U. M., Eichelbaum, M., and Murdter, T. E. (2002). The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 54, 157-167.
14. Custódio, J. A., Almeida, L. M., and Madeira, V. M. C. (1991). A reliable and rapid procedure to estimate drug partitioning in biomembranes. Biochem. Biophys. Res. Commun. 176, 1079-1085.
15. De Vos, D., Slee, P. H., Briggs, R. J., and Stevenson, D. (1998). Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels. Cancer Chemother. Pharmacol. 42, 512-514.
16. De Vos, D., Slee, P. H., Stevenson, D., and Briggs, R. J. (1992). Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 31, 76-78.
17. Decensi, A., Robertson, C., Viale, G., Pigatto, F., Johansson, H., Kisanga, E. R., Veronesi, P., Torrisi, R., Cazzaniga, M., Mora, S., Sandri, M. T., Pelosi, G., Luini, A., Goldhirsch, A., Lien, E. A., and Veronesi, U. (2003). A randomized trial of lowdose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J. Natl. Cancer Inst. 95, 779-790.
18. Desta, Z., Ward, B. A., Soukhova, N. V., and Flockhart, D. A. (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075.
19. Dorne, J. L., Walton, K., and Renwick, A. G. (2003). Human variability in CYP3A4 metabolism and CYP3A4related uncertainty factors for risk assessment. Food Chem. Toxicol. 41, 201-224.
20. Dowsett, M., Cuzick, J., Howell, A., and Jackson, I. (2001). Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br. J. Cancer 85, 317-324.
21. Dowsett, M., Tobias, J. S., Howell, A., Blackman, G. M., Welch, H., King, N., Ponzone, R., Von Euler, M., and Baum, M. (1999). The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br. J. Cancer 79, 311-315.
22. Eissing, T., Kuepfer, L., Becker, C., Block, M., Coboeken, K., Gaub, T., Goerlitz,L.,Jaeger,J.,Loosen,R.,Ludewig, B., Meyer, M., Niederalt, C., Sevestre, M., Siegmund, H. U., Solodenko, J., Thelen, K., Telle, U., Weiss, W., Wendl, T., Willmann, S., and Lippert, J. (2011). A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2:4. doi:10.3389/fphys.2011.00004
23. Etienne, M. C., Milano, G., Fischel, J. L., Frenay, M., Francois, E., Formento, J. L., Gioanni, J., and Namer, M. (1989). Tamoxifen metabolism: pharmacokinetic and in vitro study. Br. J. Cancer 60, 30-35.
24. Fabian, C., Sternson, L., El-Serafi, M., Cain,L.,and Hearne,E. (1981). Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48, 876-882.
25. Fagerberg, J. H., Tsinman, O., Sun, N., Tsinman, K., Avdeef, A., and Bergstrom, C. A. (2010). Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol. Pharm. 7, 1419-1430.
26. Fisher, B., Dignam, J., Bryant, J., and Wolmark, N. (2001). Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst. 93, 684-690.
27. Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar,Y., Fernandez Santander,A., Howell, S., Newman, W., Oyee, J., and Walley, T. (2011). The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol. Assess. 15, 1-102.
28. Fromson, J. M., Pearson, S., and Bramah, S. (1973a). The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica 3, 693-709.
29. Fromson, J. M., Pearson, S., and Bramah, S. (1973b). The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 3, 711-714.
30. Fuchs, W. S., Leary, W. P., Van Der Meer, M. J., Gay, S., Witschital, K., and Von Nieciecki, A. (1996). Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women. Arzneimittelforschung 46, 418-422.
31. Furlanut, M., Franceschi, L., Pasqual, E., Bacchetti, S., Poz, D., Giorda, G., and Cagol, P. (2007). Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther. Drug. Monit. 29, 349-352.
32. Gallicchio, L., Tkaczuk, K., Lord, G., Danton, M., Lewis, L. M., Lim, C. K., and Flaws, J. A. (2004). Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer. Cancer Lett. 211, 57-67.
33. Gjerde, J., Geisler, J., Lundgren, S., Ekse, D.,Varhaug,J. E.,Mellgren,G.,Steen, V. M., and Lien, E. A. (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313. doi:10.1186/1471-2407-10-313
34. Gjerde, J., Hauglid, M., Breilid, H., Lundgren, S.,Varhaug, J. E., Kisanga, E. R., Mellgren, G., Steen, V. M., and Lien, E. A. (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19, 56-61.
35. Goetz, M. P., Kamal, A., and Ames, M. M. (2008). Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther. 83, 160-166.
36. Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Weinshilboum, R. M., Fritcher, E. G., Nibbe, A. M., Desta, Z., Nguyen, A., Flockhart, D. A., Perez, E. A., and Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121.
37. Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A., and Ingle, J. N. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318.
38. Guerrieri-Gonzaga, A., Baglietto, L., Johansson, H., Bonanni, B., Robertson, C., Sandri, M. T., Canigiula, L., Lampreda, C., Diani, S., Lien, E. A., and Decensi, A. (2001). Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol. Biomarkers Prev. 10, 967-970.
39. Hoskins, J. M., Carey, L. A., and McLeod, H. L. (2009). CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9, 576-586.
40. Hutson, P. R., Love, R. R., Havighurst, T. C., Rogers, E., and Cleary, J. F. (2005). Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin. Cancer Res. 11, 8722-8727.
41. Irvin, W. J. Jr., Walko, C. M., Weck, K. E., Ibrahim, J. G., Chiu, W. K., Dees, E. C., Moore, S. G., Olajide, O. A., Graham, M. L., Canale, S. T., Raab, R. E., Corso, S. W., Peppercorn, J. M., Anderson, S. M., Friedman, K. J., Ogburn, E. T., Desta, Z., Flockhart, D. A., Mcleod, H. L., Evans, J. P., and Carey, L. A. (2011). Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29, 3232-3239.
42. Jaremko, M., Kasai, Y., Barginear, M. F., Raptis, G., Desnick, R. J., and Yu, C. (2010). Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal. Chem. 82, 10186-10193.
43. Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., Blanchard, R., Nguyen, A., Ullmer, L., Hayden, J., Lemler, S., Weinshilboum, R. M., Rae, J. M., Hayes, D. F., and Flockhart, D. A. (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39.
44. Johnson, M. D., Zuo, H., Lee, K. H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., and Skaar, T. C. (2004). Pharmacological characterization of 4hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159.
45. Johnston, S. R. D., Haynes, B. P., Sacks, N. P. M., Mckinna, J. A., Griggs, L. J., Jarman, M., Baum, M., Smith, I. E., and Dowsett, M. (1993). Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res. Treat. 28, 241-250.
46. Jordan, V. C. (2006). Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol. 147(Suppl. 1), S269-S276.
47. Jordan, V. C. (2007). New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72, 829-842.
48. Kaku, T., Ogura, K., Nishiyama, T., Ohnuma, T., Muro, K., and Hiratsuka, A. (2004). Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDPglucuronosyltransferase 1A4. Biochem. Pharmacol. 67, 2093-2102.
49. Kasim, N. A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A. S., Junginger, H. E., Stavchansky, S. A., Midha, K. K., Shah, V. P., and Amidon, G. L. (2003). Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1, 85-96.
50. Kim, C. S., Choi, S. J., Park, C. Y., Li, C., and Choi, J. S. (2010). Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res. 30, 79-85.
51. Kisanga, E. R., Gjerde, J., GuerrieriGonzaga, A., Pigatto, F., Pesci-Feltri, A., Robertson, C., Serrano, D., Pelosi, G., Decensi, A., and Lien, E. A. (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin. Cancer Res. 10, 2336-2343.
52. Kisanga, E. R., Mellgren, G., and Lien, E. A. (2005). Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Res. 25, 4487-4492.
53. Lammers, L. A., Mathijssen, R. H., Van Gelder, T., Bijl, M. J., De Graan, A. J., Seynaeve, C., Van Fessem, M. A., Berns, E. M., Vulto, A. G., and Van Schaik, R. H. (2010). The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br. J. Cancer 103, 765-771.
54. Langan-Fahey, S. M., Tormey, D. C., and Jordan, V. C. (1990). Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer 26, 883-888.
55. Lash, T. L., Lien, E. A., Sorensen, H. T., and Hamilton-Dutoit, S. (2009). Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10, 825-833.
56. Li, C., Lim, S. C., Kim, J., and Choi, J. S. (2011). Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur. J. Drug Metab. Pharmacokinet. 36, 175-182.
57. Lien, E. A., Anker, G., and Ueland, P. M. (1995). Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J. Steroid Biochem. Mol. Biol. 55, 229-231.
58. Lien, E. A., Solheim, E., Kvinnsland, S., and Ueland, P. M. (1988). Identification of 4-hydroxy-Ndesmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48, 2304-2308.
59. Lien, E. A., Solheim, E., Lea, O. A., Lundgren, S., Kvinnsland, S., and Ueland,P. M. (1989). Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49, 2175-2183.
60. Lim, C. K., Yuan, Z. X., Lamb, J. H., White, I. N., De Matteis, F., and Smith, L. L. (1994). A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15, 589-593.
61. Lim, Y. C., Li, L., Desta, Z., Zhao, Q., Rae, J. M., Flockhart, D. A., and Skaar, T. C. (2006). Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J. Pharmacol. Exp. Ther. 318, 503-512.
62. Madlensky, L., Natarajan, L., Tchu, S., Pu, M., Mortimer, J., Flatt, S. W., Nikoloff, D. M., Hillman, G., Fontecha, M. R., Lawrence, H. J., Parker, B. A., Wu, A. H., and Pierce, J. P. (2011). Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89, 718-725.
63. Murdter, T. E., Schroth, W., BacchusGerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T., Eichelbaum, M., Schwab, M., and Brauch, H. (2011). Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708-717.
64. Nishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., Muro, K., and Watabe, T. (2002). Reverse geometrical selectivity in glucuronidation and sulfation of cisand trans-4hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem. Pharmacol. 63, 1817-1830.
65. Peyrade, F., Frenay, M., Etienne, M. C., Ruch, F., Guillemare, C., Francois, E., Namer, M., Ferrero, J. M., and Milano, G. (1996). Agerelated difference in tamoxifen disposition. Clin. Pharmacol. Ther. 59, 401-410.
66. Piao, Y., Shin, S. C., and Choi, J. S. (2008). Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm. Drug Dispos. 29, 245-249.
67. Rae, J. M. (2011). Personalized tamoxifen: what is the best way forward? J. Clin. Oncol. 29, 3206-3208.
68. Ruiter, R., Bijl, M. J., Van Schaik, R. H., Berns, E. M., Hofman, A., Coebergh, J. W.,Van Noord, C.,Visser, L. E., and Stricker, B. H. (2010). CYP2C19+2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11, 1367-1375.
69. Seruga, B., and Amir, E. (2010). Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res. Treat. 122, 609-617.
70. Shin, S. C., and Choi, J. S. (2009). Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs 20, 584-588.
71. Shin, S. C., Choi, J. S., and Li, X. (2006). Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 313, 144-149.
72. Shin, S. C., Piao, Y. J., and Choi, J. S. (2008). Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4hydroxytamoxifen,in rats. In vivo 22, 391-395.
73. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., and Fuselli, S. (2007). CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101.
74. Soininen, K., Kleimola, T., Elomaa, I., Salmo, M., and Rissanen, P. (1986). The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients. J. Int. Med. Res. 14, 162-165.
75. Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., Hayes, D. F., Desta, Z., and Flockhart, D. A. (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764.
76. Sun, D., Sharma, A. K., Dellinger, R. W., Blevins-Primeau, A. S., Balliet, R. M., Chen, G., Boyiri, T., Amin, S., and Lazarus,P. (2007). Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab. Dispos. 35, 2006-2014.
77. Tukker, J. J., Blankenstein, M. A., and Nortier, J. W. (1986). Comparison of bioavailability in man of tamoxifen after oral and rectal administration. J. Pharm. Pharmacol. 38, 888-892.
78. Van Schaik, R. H., Kok, M., Sweep, F. C., Van Vliet, M., Van Fessem, M., Meijer-Van Gelder, M. E., Seynaeve, C., Lindemans, J., Wesseling, J., Van 't Veer, L. J., Span, P. N., Van Laarhoven, H., Sleijfer, S., Foekens, J. A., Linn, S. C., and Berns, E. M. (2011). The CYP2C19+2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 12, 1137-1146.
79. Willmann, S., Hohn, K., Edginton, A., Sevestre,M.,Solodenko,J.,Weiss,W., Lippert, J., and Schmitt, W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34, 401-431.
80. Willmann, S., Lippert, J., Sevestre, M., Solodenko, J., Fois, F., and Schmitt, W. (2003a). PK-Sim®: a physiologically based pharmacokinetic 'wholebody' model. Drug Discov. Today Biosilico 1, 121-124.
81. Willmann, S., Schmitt, W., Keldenich, J., and Dressman, J. B. (2003b). A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. 20, 1766-1771.
82. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J., and Dressman, J. B. (2004). A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47, 4022-4031.
83. Yang, S. H., Suh, J. H., and Lee, M. G. (2010). Pharmacokinetic interaction between tamoxifen and ondansetron in rats: non-competitive (hepatic) and competitive (intestinal) inhibition of tamoxifen metabolism by ondansetron via CYP2D subfamily and 3A1/2. Cancer Chemother. Pharmacol. 65, 407-418.
84. Zanger, U. M., Fischer, J., Raimundo, S., Stuven, T., Evert, B. O., Schwab, M., and Eichelbaum, M. (2001). Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585.